Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to -$13.0 million.

  • Pulse Biosciences' Cash from Operations fell 4449.25% to -$13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.5 million, marking a year-over-year decrease of 4275.92%. This contributed to the annual value of -$36.3 million for FY2024, which is 999.36% down from last year.
  • As of Q3 2025, Pulse Biosciences' Cash from Operations stood at -$13.0 million, which was down 4449.25% from -$12.8 million recorded in Q2 2025.
  • In the past 5 years, Pulse Biosciences' Cash from Operations registered a high of -$6.6 million during Q1 2023, and its lowest value of -$16.4 million during Q2 2021.
  • In the last 5 years, Pulse Biosciences' Cash from Operations had a median value of -$10.6 million in 2022 and averaged -$11.0 million.
  • In the last 5 years, Pulse Biosciences' Cash from Operations crashed by 10614.69% in 2021 and then soared by 5786.84% in 2023.
  • Quarter analysis of 5 years shows Pulse Biosciences' Cash from Operations stood at -$12.7 million in 2021, then skyrocketed by 37.25% to -$8.0 million in 2022, then rose by 14.85% to -$6.8 million in 2023, then crashed by 34.83% to -$9.1 million in 2024, then tumbled by 42.6% to -$13.0 million in 2025.
  • Its last three reported values are -$13.0 million in Q3 2025, -$12.8 million for Q2 2025, and -$13.5 million during Q1 2025.